Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

Graft Versus Host Disease Clinical Trial

— GvHD  

Official title:

Pilot Study: Sequential Administration of Allogeneic Mesenchymal Stem Cells Thawed or Expanded in Vitro for the Treatment of Acute Graft-versus-host Disease Refractory to Second Line Treatment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06304025
• Other study ID #: GvHD 01
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: June 2024
• Est. completion date: August 2025

Study information

• Verified date: March 2024
• Source: Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant hemopathies, but highlights the limitations of long-term results due to the high toxicity of the procedure and the development of Graft versus Host Disease (GVHD). Conventional treatments for GVHD have limited success rates, and some patients may be refractory to ruxolitinib, a second-line treatment option. As a result, there is a need to explore alternative immuno-modulatory therapies, such as the use of Wharton's jelly mesenchymal stem cells (WJ-MSCs).

The research question aims to investigate the safety and potential benefits of sequentially infusing thawed or expanding allogeneic WJ-MSCs in the treatment of acute GVHD refractory to second-line treatment in patients from the Colombian population. This pilot clinical study is being conducted to address the unmet need for patients who develop GVHD resistant to ruxolitinib.

Description:

In recent decades, the number of HSCTs has significantly increased, as it is considered the ideal therapeutic approach for a wide range of hematological diseases. However, GVHD is the most common and severe complication following transplantation, and it remains the major limiting factor for the success of HSCT. It has been reported that the incidence of acute GVHD is approximately 50% in patients who receive HSCT from an HLA-matched donor, and it increases in cases of HLA-mismatched donors, despite having prophylactic treatment. Patients who develop GVHD have a poor prognosis, with a survival rate ranging from 5-25% depending on the severity of the disease. This is strongly related to the lack of effective treatments. In addition to the high morbidity and mortality, GVHD represents a significant financial burden for public healthcare systems worldwide. A recent study in 2018 in the United States reported that the cost of complete remission for a 6-month period with ruxolitinib, one of the most commonly used treatments for both acute and chronic GVHD, was $1,187,657 USD.

In this context, the American Society for Blood and Marrow Transplantation considers MSCs as a prominent therapeutic tool for the treatment of GVHD, as they significantly improve both the symptoms of the most frequently affected organs (skin, liver, and intestines) and the treatment response parameters and overall survival. Colombia is not exempt from this issue; the rise of HSCT in our country is evident. Therefore, the development of a novel and effective therapeutic strategy for GVHD is a priority and demands further scientific research.

Finally, with the development of this pilot study, the aim is to lay the groundwork for conducting medium- and large-scale clinical trials in our Colombian population, where clinical studies with this type of therapeutic approach have not yet been conducted.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: August 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Aged between 18 and 65 years.

• With a diagnosis of malignant hemopathies, who have undergone allogeneic HSCT and who are diagnosed with acute GVHD refractory to second-line treatment.

• Patients who have received bone marrow and/or peripheral blood as a source of cells.

• Patients who have received cells from a family or unrelated donor

• Myeloablative or non-myeloablative conditioning method.

• Adequate cardiac function without evidence of uncontrolled hypertension, congestive heart failure, angor pectoris, or acute myocardial infarction in the 6 months prior to the process.

• Adequate lung function without evidence of severe obstructive or restrictive lung disease.

• Informed consent signed by the patient.

Exclusion Criteria:

• Patients from the Transplant Unit of the FOSCAL.

• Patients with a diagnosis of hemopathy that has not been controlled by the transplant or is progressing at the time of treatment.

• Bacterial, viral, or fungal infection that is not being controlled with adequate treatment.

• Cardiac and/or pulmonary function in uncontrolled altered conditions.

• According to medical criteria, patients who are not in an adequate situation to tolerate the treatment.

• Pregnant women or women at risk of pregnancy due to inadequate contraceptive measures.

Related Conditions & MeSH terms

• Graft Versus Host Disease
• Graft vs Host Disease

Intervention

Biological:
• Wharton's jelly mesenchymal stem cells (WJ-MSCs)
Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle	Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events: safety and tolerability	The trial's primary endpoint is to determine the safety of WJ-MSCs administration; for that, we will assess the number of treatment-related adverse events (AEs) reported according to the Common Terminology Criteria for AE classification and presentation of infectious complications after administration of WJ-MSCs.	12 months
Primary	Efficacy clinic profile: response of acute GVDH	• Response of acute GVHD refractory to second-line treatment (yes or no).	12 months
Primary	Efficacy clinic profile : duration of response	• Duration of response/incidence of relapses( time: days or months).	12 months
Primary	Efficacy clinic profile: decrease in treatments	• Decrease in corticosteroids or concomitant immunosuppressive treatment (dose).	12 months
Primary	Efficacy biological profile: secretion pattern of soluble factors	• Evolution of the secretion pattern of the following soluble factors: cytokines CK8, Reg3a, Elafina, ST2, INF-?, TNF-a, IL-12, IL-10, CXCL-9 and CXCL-10 (concentration: mg or µg or pg or others).	12 months
Primary	Efficacy biological profile: cell populations	• Determination of the following cell populations: T lymphocytes, Naive, B lymphocytes, dendritic cells, and Natural Killer cells in blood pre and post-treatment with WJ-MSCs (percentage).	12 months
Primary	Efficacy biological profile: ocrrelation of the biological markers with the clinical response	• Correlation of the profile of biological markers with the clinical response (-1 and 1).	12 months